The content on this site is intended for healthcare professionals only
Prof Wee Joo Chng speaks to ecancer about the clinical value of maintenance in multiple myeloma. Initially, he mentions the maintenance treatments he recommends for multiple myeloma patients.
Prof Chng also gives different regimen recommendation for high-risk cytogenetics patients. He discusses the phase 3 TOURMALINE-MM4 trial investigating ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT).
Prof Chng also talks about the measurable residual disease (MRD) evaluation during ixazomib (IXA) maintenance in newly diagnosed multiple myeloma (NDMM). In the end, he discusses what patient profile should receive maintenance treatments (for both the transplant eligible and ineligible) and the impact of the TOURMALINE MM3 and MM4 data in clinical practice.
| Types of maintenance treatments for MM patients | |
| Treatment recommendation for high-risk cytogenetics patients | |
| Patient profile that should receive maintenance treatments (for both the transplant eligible and ineligible) | |
| Impact of the TOURMALINE MM3 and MM4 data in clinical practice | |
| Significance of the MM4 trial data |
This programme has been supported by an unrestricted educational grant from Takeda.
Independent clones in CLL show oligoclonality and early evolution patterns
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
